

The Problem

Diseases of the nervous system are the third leading cause of premature death, after cancer and heart disease. With about 250-310 million disability-adjusted life-years (DALYs), neurological disorders are the leading cause of disability. In the EU 307 million people are affected (~60% of the population) and in 2007 the WHO estimated that neurological disorders affect up to one billion people worldwide.

Our initial and primary focus is on **multiple sclerosis (MS)**. The globally affected **2.8 million** patients experience a continuous deterioration of bodily functions ranging from paralysis and walking disability over loss of eyesight to cognitive decline.

Current treatments offer some relief, but they can **only slow down** the **disease progression**.

Our Solution

AdRegeneer's approach, in contrast, is centered around **regenerating nervous system lesions** and enabling patients to **regain lost functions**. It's a transformative approach that opens new doors to healing and recovery. It brings hope to millions of affected patients to manage MS as a chronic disease with a better quality of life. We offer state-of-the-art regenerative treatments based on **epigenetics** and gene therapy that control the program of regeneration in neural cells and thereby induce recovery and healing.

Our Assets

- A *theophylline-based* epigenetic modulator drug delivered by a remyelination-specific formulation, ready for GMP production, PI, and PII clinical trials on MS patients.
- A pipeline of six additional innovative drugs including four gene therapy drugs at different stages of pre-clinical studies
- Strong scientific backing and successful pre-clinical results
- Dedicated and experienced team members with complementary expertise
- Strong intellectual property protection with a rapidly growing portfolio

The Market Opportunity

The MS drug market will grow from ~US\$22 billion today to **~US\$32 billion** by 2030 and is dominated by a duopoly of Biogen and Roche. We do not compete against them; our unique regeneration solution is a complementary add-on therapy to their immunomodulatory treatment. AdRegeneer is therefore uniquely positioned to capture a significant share of this market. The potential applications extend beyond multiple sclerosis, with opportunities in traumatic injuries, peripheral neuropathies, other neurodegenerative diseases, and aging, providing a huge upside potential.

Investment opportunities

For our most advanced drug, we will strengthen our team, set up partnerships with patch manufacturers, and finalize GMP production in 2024. From 2025 until mid-2027 we plan to conduct Phase I and II clinical trials on multiple sclerosis patients. AdRegeneer needs to secure **€5 million** in financing for these activities in the first half of 2024. To achieve this, we are exploring different options:

1. Strategic partnership with a pharma company that covers parts of the cost and may also invest in or provide a convertible loan to an AdRegeneer subsidiary.
2. Licensing business model to one or more pharma companies.
3. Funding from investors (VCs, Business Angels, Family Offices), who are passionate about revolutionizing neuroregeneration.

Contact us

Thomas meier, Co-founder, email: thomas.meier@adregeneer.com

Claire Jacob, Co-founder, email: claire.jacob@adregeneer.com

Mert Duman, CEO, email: mert.duman@adregeneer.com